Rivastigmine Tartrate
Product Images NDC 54868-6145

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 54868-6145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label-6 mg (6mg Package Label)

This is a medication package of Rivastigmine, distributed by Physicians Total Care and labeled with an NDC code of 54868-6145-0. There is a lot number, expiration date, and weight information provided.*

FDA Label Image

Rivastigmine-figure01 (Rivastigmine Fig1)

This appears to be a graph displaying the time course of clinical improvement and decline in ADAS-cog scores for patients completing a 26-week treatment called "Changa rom Baseio". The x-axis is labeled "Weeks During Treatment" and the y-axis is labeled with "ADAS-cog Scores." There are two lines on the graph representing clinical improvement and clinical decline respectively. There is also a legend indicating the meaning of different symbols or colors used in the graph, such as "+" and "M."*

FDA Label Image

Rivastigmine-figure02 (Rivastigmine Fig2)

FDA Label Image

Rivastigmine-figure03 (Rivastigmine Fig3)

FDA Label Image

Rivastigmine-figure04 (Rivastigmine Fig4)

Figure 4 shows the time-course of change on the baseline in ADAS-cog score of a patient completing 26 weeks of treatment. There is also information on clinical improvement and clinical data during treatment.*

FDA Label Image

Rivastigmine-figure05 (Rivastigmine Fig5)

This is a chart showing the percentage of patients who completed 25 weeks of double-blind treatment with specified changes from their baseline ADAScog scores. The study had three treatment groups: Placebo, 4mg, and 12mg. The chart shows the cumulative percentage of patients completing the study along with the change in ADAScog scores. The percentage of randomized patients who completed the study for each treatment group is also provided.*

FDA Label Image

Rivastigmine-figure06 (Rivastigmine Fig6)

FDA Label Image

Rivastigmine-figure07 (Rivastigmine Fig7)

FDA Label Image

Rivastigmine-figure08 (Rivastigmine Fig8)

FDA Label Image

Rivastigmine-chemical-structure (Rivastigmine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.